- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03788486
Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device
A Phase 4 Study to Assess the Clinical Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Light Treatment Device
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will test the efficacy and safety of application of LED light to meibomian glands in upper and lower eyelids in eyes of patients suffering with meibomian gland disease.
The primary objective of the study is to investigate the safety and efficacy of blue LED light with meibomian gland expression of the upper and lower eyelids in dry eye disease by change from baseline in subjective questionnaire and by measurement of non-invasive tear break up time.
Primary Endpoint: Improvement of tear break up time over the length of the study
Secondary endpoint: subjective patient comfort over the length of the study using a validated dry eye comfort questionnaire administered at each study visit, VAS, 0= no pain and 100 = maximal discomfort, Improvement in the number of corneal SPK that stain with fluorescein.
20 study subjects 18-85 will be enrolled with male or female in the Nashville and Memphis, TN areas who are generally healthy but have signs and symptoms of dry eye disease with Meibomian gland dysfunction.
phase 4
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Toyos Clinic
-
Nashville, Tennessee, United States, 37215
- Toyos Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form and HIPPA authorization.
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 -85.
- Diagnosed with mild to severe dry eye in one or both eyes with evidence of Meibomian gland dysfunction: cloudy or thick secretions, lack of secretions or presence of telengiectasias on the lower lid margin.
- History of persistent symptoms despite use of artificial tears.
- Tear break up time of 7 seconds or less
- Have normal lid anatomy.
- Subject is able and willing to comply with the treatment, follow up schedule and requirements.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of the study.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
Are postmenopausal (no menstrual cycle for at least one year prior to Visit 1) or have undergone bilateral tubal ligation, hysterectomy, hysterectomy with uni- or bilateral oophorectomy, or bilateral oophorectomy.
-
Exclusion Criteria:
- Have a known hypersensitivity or contraindication to the investigational product or components.
- Pregnancy or lactation
- Subjects can be on the following medications if they have been on a stable dose for 12 weeks: topical cyclosporine, topical liftigrast and/or topical loteprednol etabonate. Tetracycline compounds, omega 3s, anticholinergics, anticonvulsants, antidepressants, retinoids, systemic immunosuppressive agents including oral corticosteroids, non-steroidals, antihistamines, or mast cell stabilizers, punctal plugs, contact lens wear and glaucoma medications.
- Subjects must be unwilling to abstain from eyelash growth medications for the duration of the trial.
- Subjects must not have had penetrating intraocular surgery, refractive surgery or corneal transplantation, eyelid surgery within 12 weeks prior to Visit 1.
- Febrile illness within one week.
- Treatment with another investigational drug or other intervention within one month.
- Subjects with a history of herpetic keratitis.
- Have serious or severe disease or uncontrolled medical condition that in the judgement of the investigator could confound study assessments or limit compliance.
- Neuro-paralysis or pre-cancerous lesions in the area to be treated.
- Radiation to the head or neck within past 12 months.
- Planned radiation therapy or chemotherapy.
- Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures.
- Legally blind in either eye.
- Facial IPL treatment within 3 months of treatment.
Expression of Meibomian glands within 3 months prior to treatment.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 2-3 Joule light device for MGD/Dry eye
patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month.
Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
|
application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change of non invasive tear break up time over the course of the study
Time Frame: one month
|
3 measurements of non invasive tear break up time by investigator with average recorded
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
subjective patient comfort as measured by validated VAS (visual analog scale) dry eye comfort questionnaire
Time Frame: one month
|
patient completed questionnaire 10 mm in length minimum score 0=no pain and maximal score 100= maximal pain
|
one month
|
change of number of corneal spk stained with fluorescein over the course of the study
Time Frame: one month
|
manual counting of number of corneal spk
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rolando Toyos, MD, Owner
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCQ2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meibomian Gland Dysfunction
-
Hovione Scientia LimitedCompletedMeibomian Gland Dysfunction | MGD-Meibomian Gland DysfunctionUnited States
-
University of WaterlooCompletedMeibomian Gland Dysfunction (MGD)Canada
-
Aier School of Ophthalmology, Central South UniversityUnknownMeibomian Gland Massage is Important to Delay the Development of Meibomian Gland DysfunctionChina
-
Second Affiliated Hospital, School of Medicine,...Aier Eye Hospital, WuhanCompletedMGD-Meibomian Gland DysfunctionChina
-
Barzilai Medical CenterCompletedMGD-Meibomian Gland DysfunctionIsrael
-
Singapore National Eye CentreNational University, SingaporeCompleted
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataracts | Meibomian Gland Dysfunction (MGD)United States
-
Azura OphthalmicsThe University of New South WalesCompletedMeibomian Gland Dysfunction (MGD) | Contact Lens Discomfort (CLD)Australia
-
Zhongnan HospitalRecruitingDry Eye | MGD-Meibomian Gland DysfunctionChina
-
Zhongnan HospitalRecruitingDry Eye | Positron-Emission Tomography | MGD-Meibomian Gland DysfunctionChina
Clinical Trials on 2-3 Joule LED blue light device
-
Philips Electronics Nederland BVCompletedLow Back Pain | Musculoskeletal Pain | Chronic Pain | Low Back Pain, RecurrentGermany
-
Illumacell Inc.Kerber Applied Research; Alberta Health Services - Lower Limb Wound ClinicCompletedDiabetic Foot UlcerCanada
-
University of BergenGlamoxCompletedSleep | Sleep Deprivation | Shift-Work Related Sleep DisturbanceNorway
-
Philips RespironicsCompletedSeasonal Affective DisorderUnited States
-
Northwell HealthColumbia University; National Library of Medicine (NLM)Completed
-
Philips Electronics Nederland BVUniversity Hospital, Geneva; Philipps University Marburg Medical Center; University...CompletedDermatitis, AtopicGermany, Switzerland
-
Centro de Atenção ao Assoalho PélvicoUniversity of Messina; Salvatore Giovanni Vitale M.D.RecruitingVaginosis, BacterialBrazil
-
Bispebjerg HospitalRigshospitalet, Denmark; Hvidovre University HospitalRecruitingWound Infection | Wound Heal | Phototherapy Complication | Photobiology | Light Treatment; ComplicationsDenmark
-
Mclean HospitalLiteBook Company LtdCompletedSleepiness, DaytimeUnited States
-
Charite University, Berlin, GermanyTechnische Universität BerlinRecruiting